A network meta-analysis of fulvestrant 500 mg versus alternative therapies for second-line treatment of postmenopausal, estrogen receptor-positive advanced breast cancer

被引：0
|
作者：
Telford, C.
Jones, N.
Batson, S.
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Abacus Int, Bicester, Oxon, England
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P5-14-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-14-03
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer
    Robertson, J. F. R.
    Zefei, J.
    Di Leo, A.
    Ohno, S.
    Pritchard, K. I.
    Ellis, M.
    Bradbury, I.
    Campbell, C.
    CANCER RESEARCH, 2016, 76
  • [2] Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy
    Telford, Claire
    Jones, Nick
    Livings, Christopher
    Batson, Sarah
    CLINICAL BREAST CANCER, 2016, 16 (03) : 188 - 195
  • [3] Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models
    Cope, Shannon
    Ouwens, Mario J. N. M.
    Jansen, Jeroen P.
    Schmid, Peter
    VALUE IN HEALTH, 2013, 16 (02) : 403 - 417
  • [4] A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
    Robertson, John F. R.
    Jiang, Zefei
    Di Leo, Angelo
    Ohno, Shinji
    Pritchard, Kathleen I.
    Ellis, Matthew
    Bradbury, Ian
    Campbell, Christine
    BREAST CANCER, 2019, 26 (06) : 703 - 711
  • [5] A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
    John F. R. Robertson
    Zefei Jiang
    Angelo Di Leo
    Shinji Ohno
    Kathleen I. Pritchard
    Matthew Ellis
    Ian Bradbury
    Christine Campbell
    Breast Cancer, 2019, 26 : 703 - 711
  • [6] A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer
    Generali, Daniele
    Venturini, Sergio
    Rognoni, Carla
    Ciani, Oriana
    Pusztai, Lajos
    Loi, Sherene
    Jerusalem, Guy
    Bottini, Alberto
    Tarricone, Rosanna
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (01) : 95 - 117
  • [7] A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer
    Daniele Generali
    Sergio Venturini
    Carla Rognoni
    Oriana Ciani
    Lajos Pusztai
    Sherene Loi
    Guy Jerusalem
    Alberto Bottini
    Rosanna Tarricone
    Breast Cancer Research and Treatment, 2015, 152 : 95 - 117
  • [8] Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women
    Vergote, I
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S57 - S58
  • [9] Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
    Di Leo, Angelo
    Jerusalem, Guy
    Petruzelka, Lubos
    Torres, Roberto
    Bondarenko, Igor N.
    Khasanov, Rustem
    Verhoeven, Didier
    Pedrini, Jose L.
    Smirnova, Iya
    Lichinitser, Mikhail R.
    Pendergrass, Kelly
    Garnett, Sally
    Lindemann, Justin P. O.
    Sapunar, Francisco
    Martin, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) : 4594 - 4600
  • [10] Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
    Sarah Sammons
    Noah S. Kornblum
    Kimberly L. Blackwell
    Targeted Oncology, 2019, 14 : 1 - 12
12345